CRISPR Therapeutics AG

CRISPR Therapeutics AG is a leading biotech firm that specializes in developing revolutionary gene-based medicines using its proprietary CRISPR/Cas9 gene editing platform. The company's mission is to cure genetic diseases by providing patients with a one-time treatment that can permanently correct the underlying genetic defect. CRISPR Therapeutics AG is focused on developing therapies for a range of diseases, including blood disorders, cancer, and rare genetic diseases. The company's pipeline includes several promising candidates, such as CTX001, a gene therapy for sickle cell disease and beta thalassemia, and CTX110, a CAR-T cell therapy for cancer treatment. With a team of world-class scientists and a commitment to innovation, CRISPR Therapeutics AG is at the forefront of the gene editing revolution, working to bring life-changing treatments to patients worldwide.